Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

R. Lakomý, M. Lojová, L. Souckova, L. Hynkova, K. Polachova, J. Vasina, R. Demlová, A. Poprach, J. Sana, T. Prochazka, M. Smrcka, P. Fadrus, R. Jancalek, I. Selingerova, R. Belanova, P. Slampa, P. Pospisil, T. Kazda

. 2024 ; 24 (1) : 736. [pub] 20240615

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013497

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is used for radiotherapy treatment planning. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery and is called rapid early progression (REP). Radiotherapy planning is currently based on MRI for target volumes definitions in many radiotherapy facilities. However, patients with REP may benefit from targeting radiotherapy with other imaging modalities. The purpose of the presented clinical trial is to evaluate the utility of 11C-methionine in optimizing radiotherapy for glioblastoma patients with REP. METHODS: This study is a nonrandomized, open-label, parallel-setting, prospective, monocentric clinical trial. The main aim of this study was to refine the diagnosis in patients with GBM with REP and to optimize subsequent radiotherapy planning. Glioblastoma patients who develop REP within approximately 6 weeks after surgery will undergo 11C-methionine positron emission tomography (PET/CT) examinations. Target volumes for radiotherapy are defined using both standard planning T1-weighted contrast-enhanced MRI and PET/CT. The primary outcome is progression-free survival defined using RANO criteria and compared to a historical cohort with REP treated without PET/CT optimization of radiotherapy. DISCUSSION: PET is one of the most modern methods of molecular imaging. 11C-Methionine is an example of a radiolabelled (carbon 11) amino acid commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. Optimized radiotherapy may also have the potential to cover those regions with a high risk of subsequent progression, which would not be identified using standard-of-care MRI for radiotherapy planning. This is one of the first study focused on radiotherapy optimization for subgroup of patinets with REP. TRIAL REGISTRATION: NCT05608395, registered on 8.11.2022 in clinicaltrials.gov; EudraCT Number: 2020-000640-64, registered on 26.5.2020 in clinicaltrialsregister.eu. Protocol ID: MOU-2020-01, version 3.2, date 18.09.2020.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013497
003      
CZ-PrNML
005      
20240905133915.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-024-12469-2 $2 doi
035    __
$a (PubMed)38879476
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lakomý, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic
245    10
$a 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET) / $c R. Lakomý, M. Lojová, L. Souckova, L. Hynkova, K. Polachova, J. Vasina, R. Demlová, A. Poprach, J. Sana, T. Prochazka, M. Smrcka, P. Fadrus, R. Jancalek, I. Selingerova, R. Belanova, P. Slampa, P. Pospisil, T. Kazda
520    9_
$a BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is used for radiotherapy treatment planning. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery and is called rapid early progression (REP). Radiotherapy planning is currently based on MRI for target volumes definitions in many radiotherapy facilities. However, patients with REP may benefit from targeting radiotherapy with other imaging modalities. The purpose of the presented clinical trial is to evaluate the utility of 11C-methionine in optimizing radiotherapy for glioblastoma patients with REP. METHODS: This study is a nonrandomized, open-label, parallel-setting, prospective, monocentric clinical trial. The main aim of this study was to refine the diagnosis in patients with GBM with REP and to optimize subsequent radiotherapy planning. Glioblastoma patients who develop REP within approximately 6 weeks after surgery will undergo 11C-methionine positron emission tomography (PET/CT) examinations. Target volumes for radiotherapy are defined using both standard planning T1-weighted contrast-enhanced MRI and PET/CT. The primary outcome is progression-free survival defined using RANO criteria and compared to a historical cohort with REP treated without PET/CT optimization of radiotherapy. DISCUSSION: PET is one of the most modern methods of molecular imaging. 11C-Methionine is an example of a radiolabelled (carbon 11) amino acid commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. Optimized radiotherapy may also have the potential to cover those regions with a high risk of subsequent progression, which would not be identified using standard-of-care MRI for radiotherapy planning. This is one of the first study focused on radiotherapy optimization for subgroup of patinets with REP. TRIAL REGISTRATION: NCT05608395, registered on 8.11.2022 in clinicaltrials.gov; EudraCT Number: 2020-000640-64, registered on 26.5.2020 in clinicaltrialsregister.eu. Protocol ID: MOU-2020-01, version 3.2, date 18.09.2020.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory mozku $x diagnostické zobrazování $x terapie $x radioterapie $x diagnóza $7 D001932
650    _2
$a radioizotopy uhlíku $7 D002250
650    12
$a progrese nemoci $7 D018450
650    12
$a glioblastom $x diagnostické zobrazování $x terapie $x diagnóza $x radioterapie $7 D005909
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    12
$a methionin $7 D008715
650    _2
$a PET/CT $x metody $7 D000072078
650    _2
$a prospektivní studie $7 D011446
650    _2
$a radiofarmaka $x terapeutické užití $7 D019275
650    _2
$a plánování radioterapie pomocí počítače $x metody $7 D011880
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lojová, Martina $u Department of Clinical Trials, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Souckova, Lenka $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic $u International Clinical Research Centre, St. Anne ́S University Hospital Brno, 656 91, Brno, Czech Republic
700    1_
$a Hynkova, Ludmila $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Polachova, Katerina $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vasina, Jiri $u Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic
700    1_
$a Demlová, Regina $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic $u Department of Clinical Trials, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic
700    1_
$a Sana, Jiri $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic
700    1_
$a Prochazka, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Smrcka, Martin $u Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic $u Department of Neurosurgery, University Hospital Brno, 625 00, Brno, Czech Republic
700    1_
$a Fadrus, Pavel $u Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic $u Department of Neurosurgery, University Hospital Brno, 625 00, Brno, Czech Republic
700    1_
$a Jancalek, Radim $u Department of Neurosurgery, St. Anne's University Hospital Brno, 656 91, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic
700    1_
$a Selingerova, Iveta $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic
700    1_
$a Belanova, Renata $u Department of Medical Imaging, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic
700    1_
$a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Pospisil, Petr $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic. tomas.kazda@mou.cz $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic. tomas.kazda@mou.cz $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. tomas.kazda@mou.cz
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 24, č. 1 (2024), s. 736
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38879476 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133909 $b ABA008
999    __
$a ok $b bmc $g 2143363 $s 1225363
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 1 $d 736 $e 20240615 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace